FierceBiotechOriginal article
{"a":[{"_":"Sanofi suspends chronic lung disease phase 2 study, tied to ‘strategic business reasons’","$":{"href":"/biotech/sanofi-suspends-chronic-lung-disease-phase-2-study-tied-strategic-business-reasons","hreflang":"en"}}]}
Phase 2negativeSAR445399Negative
AI Analysis
Summary
Sanofi has suspended a phase 2 trial of SAR445399, a monoclonal antibody for non-cystic fibrosis bronchiectasis, citing strategic business reasons. The trial halt represents a setback for the chronic lung disease program.
Clinical Trial Data
Phase
2
Outcome Details
Phase 2 trial suspended due to strategic business reasons
Importance:5/10
Sentiment:
-0.60
trial suspensionmonoclonal antibodychronic lung diseasestrategic decision
Related Companies
Read the original article
Published by FierceBiotech on August 5, 2026 2:08 PM